19.64
Schlusskurs vom Vortag:
$19.90
Offen:
$19.95
24-Stunden-Volumen:
692.41K
Relative Volume:
0.30
Marktkapitalisierung:
$2.47B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-9.6771
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-2.05%
1M Leistung:
+5.48%
6M Leistung:
-34.57%
1J Leistung:
-47.50%
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
APLS
Apellis Pharmaceuticals Inc
|
19.65 | 2.50B | 715.22M | -250.10M | -205.58M | -2.03 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.84 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
570.82 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.50 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.96 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-10-16 | Eingeleitet | William Blair | Outperform |
2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-11-09 | Eingeleitet | Goldman | Buy |
2023-11-02 | Eingeleitet | Mizuho | Neutral |
2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-08-29 | Bestätigt | Citigroup | Buy |
2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
2022-06-17 | Fortgesetzt | Stifel | Buy |
2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
2021-09-10 | Bestätigt | Credit Suisse | Neutral |
2021-09-10 | Bestätigt | Needham | Buy |
2021-09-10 | Bestätigt | Oppenheimer | Outperform |
2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
2021-08-19 | Eingeleitet | Jefferies | Buy |
2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
2021-05-21 | Eingeleitet | UBS | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2020-11-19 | Eingeleitet | Needham | Buy |
2020-09-01 | Eingeleitet | Stifel | Buy |
2020-07-20 | Eingeleitet | ROTH Capital | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Neutral |
2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
2019-11-22 | Eingeleitet | Wedbush | Underperform |
2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times
Is Apellis Pharmaceuticals Inc. a good long term investmentDynamic investment growth - jammulinksnews.com
What analysts say about Apellis Pharmaceuticals Inc. stockFree Popular Stock Recommendations - jammulinksnews.com
Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com
What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com
Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech
APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times
Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - Insider Monkey
Apellis stock surges after Sobi $300 million royalty deal - MSN
Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale
(APLS) Trading Advice - news.stocktradersdaily.com
Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq
Mizuho maintains Neutral rating on Apellis stock amid royalty deal with Sobi - Investing.com Canada
Apellis to receive $300 million in royalty deal with Sobi By Investing.com - Investing.com South Africa
Apellis to receive $300 million in royalty deal with Sobi - Investing.com India
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Francois Cedric | Chief Executive Officer |
Jul 17 '25 |
Sale |
20.21 |
19,725 |
398,735 |
331,605 |
Watson David O. | General Counsel |
Jul 16 '25 |
Sale |
19.55 |
5,000 |
97,750 |
128,730 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):